# Glecaprevir + Pibrentasvir

## Maviret 100/40mg

| TAH Drug Code      | [OMAV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMAV)                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | MAVIRET is indicated for the treatment of chronic hepatitis C virus (HCV) infection of genotypes 1， 2， 3， 4， 5， or 6 in patients aged 12 years and older.                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Adults and children > or = 12 years: 3 tablets PO once daily with meals (total daily dose: glecaprevir 300 mg， pibrentasvir 120 mg) for 8-16 weeks.                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | MAVIRET is contraindicated in patients with known hypersensitivity to the active ingredients or any excipients. MAVIRET is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C) or those with a history of hepatic decompensation. MAVIRET must not be co-administered with medicinal products containing atazanavir， simvastatin， dabigatran etexilate， medicinal products containing more than 20 μg of ethinyl estradiol， or rifampicin. |
| Adverse Effects    | Headache， fatigue， Nausea， diarrhea                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/glecaprevir-and-pibrentasvir-drug-information)                                                                                                                                                                                                                                                                                                                                                                                           |

